Sale!

PPP2R2B Gene Spinocerebellar Ataxia Type 12 Autosomal Dominant Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The PPP2R2B gene is associated with Spinocerebellar Ataxia Type 12 (SCA12), a rare hereditary disorder characterized by progressive degeneration of the cerebellum, the part of the brain that is responsible for coordinating movement. This condition typically manifests as tremors, unsteady gait, and difficulty with fine motor tasks. SCA12 is an autosomal dominant condition, meaning that an individual only needs a single copy of the altered gene from one parent to be affected.

To diagnose this condition, a genetic test targeting the PPP2R2B gene can be conducted. This test looks for specific mutations in the gene that are known to cause SCA12. Identifying these mutations can confirm a diagnosis, help assess the risk of passing the condition to offspring, and aid in the management and treatment of symptoms.

In the United Arab Emirates, DNA Labs UAE offers this specific genetic test. The cost of the test is 4400 AED. DNA Labs UAE is equipped with state-of-the-art technology to provide accurate and reliable genetic testing services. By opting for this test, individuals who have a family history of SCA12 or exhibit symptoms associated with the condition can gain valuable insights into their genetic makeup, enabling informed decisions regarding their health and future.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

PPP2R2B Gene Spinocerebellar Ataxia Type 12 Autosomal Dominant Genetic Test

At DNA Labs UAE, we offer the PPP2R2B Gene Spinocerebellar Ataxia Type 12 Autosomal Dominant Genetic Test at a cost of 4400.0 AED. This test is specifically designed to diagnose and detect the symptoms of spinocerebellar ataxia type 12 (SCA12), an autosomal dominant neurodegenerative disorder that primarily affects the cerebellum.

Test Details

The PPP2R2B gene is associated with SCA12. Our Next-Generation Sequencing (NGS) technology allows us to analyze multiple genes simultaneously, specifically targeting the PPP2R2B gene for any potential disease-causing mutations.

The testing process involves obtaining a DNA sample, which can be done through a blood or saliva sample. The DNA is then sequenced using NGS technology to identify any variations or mutations in the PPP2R2B gene. These variations or mutations can help confirm a diagnosis of SCA12 or provide information about the individual’s risk of developing the condition.

NGS genetic testing for SCA12 is particularly useful in cases where the symptoms are not clear-cut or when there is a family history of the condition. It can also provide important information for genetic counseling and family planning, as it can identify individuals who may be at risk of passing on the condition to their children.

Please note that genetic testing for SCA12 should be performed by a healthcare professional or a specialized genetic testing laboratory. The results of the test should be interpreted by a qualified healthcare provider who can provide appropriate counseling and guidance based on the individual’s specific situation.

Pre Test Information

Before undergoing the PPP2R2B Gene Spinocerebellar Ataxia Type 12 Autosomal Dominant Genetic Test, it is important to provide a clinical history of the patient. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected with SCA12.

Test Information

  • Test Name: PPP2R2B Gene Spinocerebellar Ataxia Type 12 Autosomal Dominant Genetic Test
  • Components: NGS Technology
  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Test Type: Neurological Disorders
  • Doctor: Neurologist
  • Test Department: Genetics

For more information or to schedule an appointment, please contact our genetics department.

Test Name PPP2R2B Gene Spinocerebellar ataxia type 12 autosomal dominant Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for PPP2R2B Gene Spinocerebellar ataxia type 12, autosomal dominant NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with PPP2R2B Gene Spinocerebellar ataxia type 12, autosomal dominant
Test Details

The PPP2R2B gene is associated with spinocerebellar ataxia type 12 (SCA12), an autosomal dominant neurodegenerative disorder that primarily affects the cerebellum.

NGS (Next-Generation Sequencing) genetic testing is a technique used to analyze multiple genes simultaneously to identify genetic variations or mutations that may be associated with a particular condition. In the case of SCA12, NGS genetic testing can be used to analyze the PPP2R2B gene for any potential disease-causing mutations.

The testing process involves obtaining a DNA sample, usually through a blood or saliva sample, from the individual being tested. The DNA is then sequenced using NGS technology to identify any variations or mutations in the PPP2R2B gene. These variations or mutations can help confirm a diagnosis of SCA12 or provide information about the individual’s risk of developing the condition.

NGS genetic testing for SCA12 can be helpful in confirming a diagnosis, especially in cases where the symptoms are not clear-cut or when there is a family history of the condition. It can also provide important information for genetic counseling and family planning, as it can identify individuals who may be at risk of passing on the condition to their children.

It’s important to note that genetic testing for SCA12 is typically performed by a healthcare professional or a specialized genetic testing laboratory. The results of the test should be interpreted by a qualified healthcare provider who can provide appropriate counseling and guidance based on the individual’s specific situation.